



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/543,070	07/22/2005	William H Bullock	5147	1198
35969	7590	04/23/2008	EXAMINER	
Bayer Health Care LLC			AULAKH, CHARANJIT	
400 Morgan Lane			ART UNIT	PAPER NUMBER
West Haven, CT 06516			1625	
			MAIL DATE	DELIVERY MODE
			04/23/2008	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/543,070	BULLOCK ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Charanjit S. Aulakh	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-22 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) 1-5 is/are allowed.
- 6) Claim(s) 6-22 is/are rejected.
- 7) Claim(s) \_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. ____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>7/22/05</u> .	6) <input type="checkbox"/> Other: ____ .

## **DETAILED ACTION**

1. Claims 1-22 are pending in the application.

### ***Specification***

2. This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

3. The attempt to incorporate subject matter into this application by reference to provisional application is ineffective because the number ( 60/455,194 ) of this provisional application is wrong. It should be 60/458,194.

### ***Claim Rejections - 35 USC § 112***

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 6-15, 17 and 18 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The following eight different factors (see *Ex parte Foreman*, 230 USPQ at 547; *Wands*, *In re*, 858.F. 2d 731, 8 USPQ 2d 1400, Fed. Cir. 1988) must be considered in order for the specification to be enabling for what is being claimed:

Quantity of experimentation necessary, the amount of direction or guidance provided, presence or absence of working examples, the nature of the invention, the state of the

prior art, the relative skill of those in the art, the predictability or unpredictability and the breadth of claims. In the instant case, the specification is not enabling based on atleast four of the above mentioned eight different factors such as quantity of experimentation necessary, the amount of direction or guidance provided, presence of working examples, state of the prior art, unpredictability and the breadth of claims.

The specification mentions on page 49, lines 3-5 that compounds 2, 6-10 and 12 were found to stimulate insulin release about 1.3 to 2-fold over basal insulin release.

However, no actual data is present in the specification. The applicants are suggested to present this data in an affidavit form since they do have this data. What are the basal levels of insulin and what is the effect of vehicle only which is used to dissolve the instant compounds. Is there significant difference between the vehicle treatment versus treatment with compounds 2, 6-10 and 12 on the insulin levels. There is no teaching or guidance present in the specification that insulin stimulating effect of instant compounds will either be maintained or further enhanced in combination with any other drug. There is no teaching either in the specification or prior art that enhancement of insulin release in vitro is a well established and well excepted assay for determining the therapeutic utility of novel compounds for treating diabetes and related disorders. There is no teaching either in the specification or prior art that structurally closely related compounds are well known to have therapeutic utility for treating diabetes and all related disorders. There are no working examples present showing efficacy of instant compounds either alone or in combination with any other drug n animal models of diabetes, syndrome X or any related disorder. The instant compounds of formula (I)

encompasses hundreds of thousands of compounds based on the values of variables R1-R7 and therefore, in absence of such teachings, guidance and presence of working examples, it would require undue experimentation to demonstrate the efficacy of instant compounds either alone or in combination with thousands of other drugs mentioned in claims 6, 7, 13 and 14 in animal models of diabetes and all related disorders and hence their utility for treating these disorders.

In regard to prophylaxis, it is well known in the art that the etiology of any known disease condition including diabetes involves multiple mechanisms. Therefore, correcting only one of these several mechanisms will not completely cure ( prevent ) that disease condition.

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 8, 11, 14 and 16-22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claims 8, 11, 14 and 17, the term ---- diabetes-related disorders ---- is indefinite since these disorders are not defined.

In claims 16 and 18, the term ---- medicament ---- is vague. The applicants are suggested to use the term --- A pharmaceutical composition -----.

In claims, 19-22, the term ---- of the present invention ---- is vague and indefinite since the variables R1, R3-R7, R4-1 and R4-2 are not defined in independent claim 19.

Claim 17 provides for the use of compounds, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

***Claim Rejections - 35 USC § 101***

8. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

9. Claim 17 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

***Allowable Subject Matter***

10. The following is a statement of reasons for the indication of allowable subject matter: Claims 1-5 are allowed since the instant compounds of formula (I) and pharmaceutical compositions containing these compounds are neither disclosed nor obvious over the prior art. In the prior art, Shibuya ( JP 07126268, cited on applicant's form 1449 ) discloses naphthyridine derivatives as inflammation inhibitors which are closely related to the instant compounds. However, the compounds of Shibuya ( see compounds 1-72 on pages 9-37 ) differ from the instant compounds in having different value of instant variable R3 ( alkyl or substituted alkyl group instead of hydrogen ) and

furthermore, there is no teaching, guidance or motivation in the prior art to modify the compounds of Shibuya to prepare the instant compounds.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571)272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Charanjit S. Aulakh/  
Primary Examiner, Art Unit 1625